ritic plaque deposition are not just parallel processes but reflect additive pathological cascades that influence the course of clinical AD manifestation. Further inquiry into the role of CAA and its contribution to early cognitive change in AD is suggested.
mains (perceptual speed and episodic memory) independent of pathological Aβ load [8] . However, it has recently been suggested that vascular and amyloid pathology independently predict cognitive decline. Vemuri et al. [9] used white matter lesion volume as a proxy measure of vascular change. Though this captures small infarcts associated with cerebrovascular disease, it does not directly assess the interaction of Aβ and the cerebrovasculature.
Despite increased interest in the role of CAA in cognitive decline, we still know little about its influence on the clinical manifestation of AD. To begin to address this gap in our knowledge, we retrospectively assessed the age of cognitive change onset, age of later stage AD and rate of dementia progression in a large, well-characterized cohort of older adults. We hypothesized that those who had CAA (characterized neuropathologically by brain autopsy) would experience earlier AD-related cognitive change and have a faster rate of dementia progression after diagnosis.
Methods
We used the National Alzheimer's Coordinating Center's (NACC) data set compiled in December 2014. The data are collected under the cooperative agreement (U01 AG016976) by member institutions approved under their respective institutional review boards. The NACC data set includes over 30,000 subjects, most characterized longitudinally by the network of AD centers throughout the country using standardized reporting tools [10] .
We first excluded records without neuropathology autopsy data. We then calculated the age at each visit as the difference between the birth month and visit month at mid-month for each record and excluded records from individuals under 60 years of age. We also excluded subjects with a major brain infarct at autopsy (database field name NACCINF = 0). Finally, we included only those individuals who were evaluated as having normal cognition at all evaluations (NORMCOG = 0 and CDRGLOB = 0) or were characterized as having amnestic mild cognitive impairment (MC-IAMEM, MCIAPLAN, MCIAPATT, MCIAPEX or MCIAPVIS = 1) or probable AD as a primary cause of cognitive change (PRO-BAD = 1 and PROBADIF = 1) at any visit. We identified the last known age of normal cognition, the first known age of amnestic mild cognitive impairment or probable AD, and the first known age at which their dementia was rated at moderately severe (CDRGLOB ≥ 2).
We categorically coded data based on the neuropathological determination of the presence and severity of CAA and neocortical Aβ NP at autopsy. We classified subjects with CAA burden defined as 'none' or 'mild' as CAA-(database field name NACCAMY <2). We classified subjects with NP burden defined as 'none' or 'mild' as NP-(NACCNEUR <2). We then grouped subjects based on the classifications: no significant CAA or NP burden (CAA-/NP-), no significant CAA burden but significant NP burden (CAA-/NP+), significant CAA burden with no NP burden (CAA+/NP-) and significant CAA and NP burden (CAA+/NP+).
Group demographics were compared using standard parametric and nonparametric tests as appropriate. CAA and NP burdens were compared using Spearman's rank-order test. Because the exact age of cognitive change onset and age of moderate-stage dementia were either left-censored (patients had already experienced the events at their first visit), interval-censored (event occurred between visits) or right-censored (events were not observed by the last follow-up visit), we assessed differences in the age of cognitive change onset and the age of moderate-stage dementia based on the presence of neuropathology using parametric regression with various distributions: exponential, gamma, log-logistic, log-normal and Weibull selected using Bayesian information criterion. This allowed us to take advantage of the larger, censored data set. The models included main effects of sex, race (nonwhite vs. white), education, hypertension (active or remove vs. none) and hypercholesterolemia (active or remove vs. none) and included two-way interactions. Post hoc comparisons across groups were conducted by regression analysis. We also performed an analysis confined to subjects who had Clinical Dementia Rating (CDR) of 0.5 initially or showed CDR 0.5 during follow-up visits, and we estimated the time of progression from CDR 0.5 to CDR ≥ 2. By definition, this time to progression was the difference in the corresponding censored ages.
To ease communication of the analyses, we used the following notations:
T 1 = the last known age of normal cognitive status; T 2 = the first known age of cognitive status change; T 3 = the last known age of CDR <2; T 4 = the first known age of CDR ≥ 2. The age of cognitive status change was interval-censored if both T 1 and T 2 were available, right-censored if T 1 was available but T 2 was missing or left-censored if T 2 was available but T 1 was missing. The age of moderate dementia onset can be interpreted in the same manner using T 3 and T 4 instead of T 1 and T 2 .
Building on this notation, we also calculated a time of progression from available information:
T 5 = T 3 -T 2 , the time elapsed in early-stage AD; T 6 = T 4 -T 1 , the time elapsed from normal cognition to moderate-stage dementia if T 1 and T 4 were available (cognitive status change and moderate dementia were both interval-censored). Alternatively, T 6 was coded as missing if T 4 was missing (rightcensored age of moderate-stage dementia). For observations with T 4 available but missing T 1 , we computed T 6 = T 4 -T 2 as a proxy measure. As the analyses for age of cognitive change and age of moderate-stage dementia, the (T 5 , T 6 ) pairs were used in parametric regression to incorporate interval-and right-censored observations. When T 2 = T 3 and T 6 was not missing, we set T 5 = 0.1 to avoid the observations being excluded from the analysis.
Results
Our sample included only those with normal cognition or AD-related cognitive change (n = 1,439), excluding individuals who reverted to normal status at any visit. We excluded 25 subjects with no CAA classification, leaving a sample of 1,414. The mean follow-up period of these 1,414 subjects was 3.0 years (standard deviation, SD = 2.1). Table 1 summarizes the dementia stage progression of our sample. An additional 22 subjects without information on education, hypertension and/or hypercholesterolemia were further excluded from the regression analyses, resulting in a sample size of 1,392. Table 2 presents demographic data for the sample and notes the number of missing values in each descriptor. Individuals with CAA+/NP+ had an earlier age of enrollment and an earlier age of death ( table 2 , p < 0.001). Race was marginally significantly different between the groups, largely driven by a higher proportion of nonwhite individuals classified as CAA+/NP-[χ 2 (3) = 6.2, p = 0.10]. As expected, individuals with an ApoE4 allele were more likely to be categorized as having significant CAA or NP burden [χ 2 (3) = 150.6, p < 0.001]. The CAA burden was only moderately correlated with the NP burden, even after controlling for age of death and ApoE4 carrier status (rho = 0.36, p < 0.001).
Age of AD-Related Cognitive Change Onset
The estimates for the median age of cognitive change onset were before 62.4 years (CAA-/NP+), before 69.9 years (CAA+/NP+), before 76.7 years (CAA+/NP-) and 80.4 years (CAA-/NP-). See figure 1 for the cumulative probability plots of age of cognitive change. Only the CAA-/NP-curve intersects at 50% cumulative probability, at 80.4 years. Because more than half of the observa- tions were left-censored for all other groups (most subjects had already experienced cognitive change before enrollment), their curves do not reach 50% cumulative probability. Thus, the reported, estimated median age of cognitive change and the intersections at 0.5 cumulative probability are interpolations and likely to be skewed. We then tested the age of cognitive change onset against our neuropathological classification groups, accounting for sex, race, education, hypertension and hypercholesterolemia. Women (hazard ratio, HR = 0.40, p < 0.001) and those with more education were more likely to experience cognitive change onset at a later age (HR = 0.90, p < 0.001). Nonwhite subjects seemed to have a greater risk of cognitive change at an earlier age (HR = 2.68, p = 0.04), but this effect should be interpreted with caution due to low sample size. Subjects with hypercholesterolemia also tended to be at risk for earlier age of cognitive change onset (HR = 1.65, p = 0.005), whereas subjects with hypertension showed lower risks than their counterparts (HR = 0.69, p = 0.03). We found that after accounting for sex, race, education, hypertension and hypercholesterolemia, both CAA status [χ 2 (1) = 7.7, p = 0.006] and NP status [χ 2 (1) = 55.1, p < 0.001] were significant factors affecting age of cognitive change. The post hoc comparisons indicated that CAA+/NP+ individuals were more likely to experience cognitive change earlier than those with NP+ alone (HR = 2.0, p = 0.006) or CAA+ alone (HR = 13.9, p < 0.0001) and much more likely to experience cognitive change than those with no little or no neuropathological burden (CAA-/NP-, HR = 19.2, p < 0.001). Individuals with NP+ alone had higher risks of cognitive change than those with CAA+ alone (HR = 6.8, p < 0.0001) and CAA-/NP-individuals (HR = 9.4, p < 0.0001), but there was no significant difference between those with CAA+ alone and those with CAA-/NP-(HR = 1.4, p = 0.39). These post hoc comparisons revealed an order of risk for earlier cognitive change: CAA+/NP+, CAA-/NP+, and NP-(either with or without CAA+).
Age of Moderate-Stage Dementia
Our next question was whether individuals with CAA experience more rapid decline. In order to capitalize on the large NACC data set, we first investigated the estimated age of conversion to moderate-stage dementia. This does not directly address the rate of progression but, coupled with the age of onset, provides some estimate of progression.
The estimates for the median age of moderate-stage dementia were 77.5 years (CAA+/NP+), >110.0 years (CAA+/NP-), 81.4 years (CAA-/NP+) and >104 years (CAA-/NP-). Figure 2 shows the estimated cumulative probabilities versus age. Note that there were only 4 observations with the last known age >100 years for the CAA+/NP-and CAA-/NP-groups. Thus, the reported estimates for the median age of conversion to moderatestage dementia are interpolations.
We then tested moderate-stage dementia classification against our neuropathological classification groups, accounting for sex, education, race, hypertension and hypercholesterolemia. As with our first analysis, we found that being male (HR = 1.29, p = 0.0007), nonwhite (HR = 1.52, p = 0.007), and having hypercholesterolemia (HR = 1.23, p = 0.007) were associated with a greater risk of earlier moderate-stage dementia classification. More years of education (HR = 0.95, p < 0.0001) and having hypertension (HR = 0.80, p = 0.003) were associated with a lower likelihood of early moderate-stage dementia classification. After accounting for sex, race, education, hypertension and hypercholesterolemia, both CAA status [χ 2 (1) = 13.6, p = 0.0002] and NP status [χ 2 (1) = 119.8, p < 0.0001] were significant factors influencing age of moderate-stage dementia classification. As in the analysis of age of cognitive change onset, the post hoc compari- Table 3 presents demographic data for the direct comparison of rates of dementia progression (n = 290). We combined subjects classified as CAA+/NP-with CAA-/ NP-due to low numbers of subjects (n = 8). The overall differences across the 3 groups were marginally significant (p = 0.051). Post hoc comparisons indicated a trend of high risk of faster progression in CAA-/NP+ versus all NP-subjects (HR = 1.85, p = 0.022 > 0.05/3 by Bonferroni correction). Other comparisons were not significant: CAA-/NP+ versus CAA+/NP+ subjects (HR = 1.33, p = 0.14) and CAA+/NP+ versus NP-subjects (HR = 1.39, p = 0.24). The conclusions remained the same when covariates of sex, race, education, hypertension and hypercholesterolemia were adjusted.
Rate of Dementia Progression

Discussion
We used a large cohort of individuals with neuropathological characterization to explore the relationship of CAA to cognitive change onset and rate of dementia progression in the absence of major infarcts. Our goal was to determine whether CAA meaningfully contributed to an earlier onset or faster progression of AD-related dementia. We found that having significant loads of CAA and NP posed the greatest risk for cognitive change at an earlier age. However, for those with CAA, the risk of conversion to moderate-stage dementia was only slightly greater than those without. Our direct assessment of progression in a smaller sample found that those with NP but without significant CAA were at the greatest risk for faster progression. In fact, those who were both CAA+ and This plot shows the cumulative probability of moderatestage dementia (CDR 2) classification against age for each of our neuropathological classifications: no significant CAA or NP burden (CAA-/NP-, dotted), no significant CAA burden but significant NP burden (CAA-/NP+, long dash/short dash), significant CAA burden with no NP burden (CAA+/NP-, medium dash) and significant CAA and NP burden (CAA+/NP+, solid). The light gray horizontal line denotes at least 50% of individuals experiencing moderate-stage dementia. Note again how the CAA+/NP+ and CAA-/NP+ groups have a high likelihood for experiencing earlier classification as moderately demented. We found that only NP+ was associated with this classification, not CAA+ status. NP+ exhibited slightly slower progression than those who were only NP+. Our findings support the relationship between CAA and early cognitive change compared to those without neuropathological burden [8] , while de-emphasizing its role in explaining the speed of dementia progression. We speculate that evidence of CAA may have a greater impact early, possibly through reducing cognitive reserve, a construct that explains maintained cognition despite neuropathological brain damage [11] . Indeed, previous studies suggest that conditions associated with vascular compromise (e.g. diabetes) result in an earlier but slower decline [12, 13] . It is also possible that after reaching a certain threshold of vascular Aβ clearance, nonvascular tissue instead become the primary accumulation site [14] . Aggregation-prone peptides such as Aβ exhibit different kinetics for deposition (or 'seeding') and growth [15] , and often eventually plateau in concentration [10] . Once in vessels, CAA-related effects on blood flow could slow the clearance of extracellular proteins such as Aβ, increasing their concentration in the parenchyma [16] . The importance of blood vessels in Aβ clearance is underscored by studies using Aβ immunotherapy agents -when Aβ is cleared from the parenchyma, deposition is increased in the perivascular pathways [17] . The potential saturation of the vessel may have consequences for Aβ clearance as a treatment avenue [18] .
Though intriguing, this analysis has several limitations to consider. The cohort was well characterized over a long period under highly standardized methods across many sites. Despite this, there could be differences based on the demographics of the regional subject population. Our sample was predominantly white, non-Hispanic, thus limiting generalization to the broader population. Finally, though the NACC data set is among the largest longitudinal data sets of AD and cognitive aging characterization in the world, it is subject to selection bias. Our results are probably influenced by the socioeconomic and emotional factors involved in who elects to enter the study and when. This can be most clearly seen in our cumulative probability functions and estimated median ages of conversion. Several of these ages are inconsistent with clinical presentation. Most subjects had already experienced cognitive change: 83% left-censored data. Thus, estimates of conversion age are interpolations and should be interpreted with caution. Further, the majority of individuals who entered the study who ultimately proved to have significant NP burden, with or without CAA, were younger. This may reflect a younger population seeking entry in clinical trials [19] . Values are means ± SD or n (%), except when noted. 1 The CAA+/NP-group was combined with CAA-/NP-due to few observations.
Our findings support the belief that CAA contributes to significant changes in early AD pathogenesis. Importantly, the results support that vascular amyloidosis and NP deposition are not just parallel processes but additive pathological cascades that influence the course of clinical change. Cerebral amyloid deposition may shift dementia onset and conversion to moderate-stage dementia to a younger age. These findings require further investigation into the relationship of CAA and neuritic plaque burden on the clinical expression of AD.
